Nasdaq suspends Windtree (WINT): -80% in 24 hours, moving to OTC and BNB strategy in jeopardy

Related

LayerZero dispute deepens after $290 million rsETH bridge drain

Kelp DAO is challenging layerzero‘s account of a $290...

Stablecoin bill could slip into May as bank lobbying intensifies

The stablecoin bill could miss its expected April review...

Circle’s USDC Bridge cuts cross-chain friction across 17+ networks

Circle has launched its USDC Bridge, a consumer-facing tool...

Bitget says tokenized markets are reshaping macro hedging as volume hit $6B

Bitget and Block Scholes say tokenized markets are becoming...

Bitcoin toward $90,000: whales accumulate 270,000 BTC and the market heats up

In the last thirty days, the cryptocurrency market has...

Share

The suspension from Nasdaq for Windtree Therapeutics (ticker WINT), due to non-compliance with listing requirements and accompanied by an intraday collapse of –80%, has sparked strong fears among investors and raised questions about the recent initiative of treasury in BNB (initial commitment of $60 million with potential up to $200 million), indicating an already fragile financial balance.

According to the collected data, the stock went from about $0.48 before the notice to $0.11 at the close on August 21, 2025, confirming the very substantial intraday loss. Industry analysts monitoring small-cap biotech companies note that similar situations typically lead to a compression of capitalization and a significant reduction in liquidity in the first weeks following the delisting.